Male hypogonadism and metabolic syndrome. (9th July 2014)

• Record Type: Journal Article
• Authors: Naifar, M.; Rekik, N.; Messedi, M.; Chaabouni, K.; Lahiani, A.; Turki, M.; Abid, M.; Ayedi, F.; Jamoussi, K.
• Is Part Of: Andrologia. Volume 47:Number 5(2015)
• Page Start: 579
• Page End: 586
• Publication Date: 2014-07-09
• Subjects: Cardiovascular disease -- insulin resistance -- male hypogonadism -- metabolic syndrome; Andrology -- Periodicals; Infertility, Male -- Periodicals; 616.69
• DOI: 10.1111/and.12305
• Languages: English
• ISSNs: 0303-4569

Abstract

Summary: The role of androgens in cardiovascular disease is still controversial in men. In this study, we investigated metabolic disorders in Tunisian hypogonadal men compared with healthy controls. Forty hypogonadal men and 80 control subjects were enrolled. Patients with a history of pre‐existing panhypopituitarism, thyroid dysfunction or inflammatory disease were excluded. Glycaemia, glycated haemoglobin (HbA1c), high‐sensitive C‐reactive protein (hsCRP), lipid profile, insulin, testosterone and gonadotrophins were measured. Insulin resistance was assessed by homoeostasis model assessment of insulin resistance (Homa IR). Waist circumference, body mass index and blood pressure were significantly higher in patients compared with controls. Glycemia, HbA1c, fasting serum insulin and Homa IR were significantly increased among hypogonadal men. In univariate analysis, testosterone levels were inversely correlated with body mass index, waist circumference, blood pressure, glycaemia, HbA1C, insulin, Homa IR and hsCRP. In multivariate analysis including all significant variables, initial testosterone level was the only independent risk factor for developing dyslipidaemia. With logistic regression, male hypogonadism was an independent risk factor for MS ( P < 0.001). We conclude that low testosterone level plays a central role in the development of metabolic syndrome. Further prospective data are required to establish the causative link.